William Blair analyst Robert Napoli initiates coverage on Ncino (NASDAQ:NCNO) with a Outperform rating.
Merck Keeps M&A Mode On With Mirati, Biogen, mRNA Companies On Radar: FT
Merck & Co Inc (NYSE: MRK) remains in a deal-hunting mode despite its recent $11.5 billion acquisition of Acceleron.